Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction with Dietary Metabolic Challenge by Miller, E. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/98429  
 
Edward J. Miller, Timothy Calamaras, Aly Elezaby, Aaron Sverdlov, Fuzhong Qin, Ivan Luptak, Ke 
Wang, Xinxin Sun, Andrea Vijay, Dominique Croteau, Markus Bachschmid, Richard A. Cohen, Kenneth 
Walsh, Wilson S. Colucci 
Partial liver kinase B1 (LKB1) deficiency promotes diastolic dysfunction,de novo systolic 
dysfunction, apoptosis, and mitochondrial dysfunction with dietary metabolic challenge 
Journal of the American Heart Association, 2016; 5(1):e002277-1-e002277-26 
© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. 
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial 
License, which permits use, distribution and reproduction in any medium, provided the original work 
is properly cited and is not used for commercial purposes. 




























Partial Liver Kinase B1 (LKB1) Deﬁciency Promotes Diastolic
Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and
Mitochondrial Dysfunction With Dietary Metabolic Challenge
Edward J. Miller, MD, PhD; Timothy Calamaras, BS, PhD; Aly Elezaby, BS; Aaron Sverdlov, MD, PhD; Fuzhong Qin, MD, PhD;
Ivan Luptak, MD, PhD; Ke Wang, MD; Xinxin Sun, MD; Andrea Vijay, BS; Dominique Croteau, BS; Markus Bachschmid, PhD;
Richard A. Cohen, MD; Kenneth Walsh, PhD; Wilson S. Colucci, MD
Background-—Myocardial hypertrophy and dysfunction are key features of metabolic heart disease due to dietary excess.
Metabolic heart disease manifests primarily as diastolic dysfunction but may progress to systolic dysfunction, although the
mechanism is poorly understood. Liver kinase B1 (LKB1) is a key activator of AMP-activated protein kinase and possibly other
signaling pathways that oppose myocardial hypertrophy and failure. We hypothesized that LKB1 is essential to the heart’s ability to
withstand the metabolic stress of dietary excess.
Methods and Results-—Mice heterozygous for cardiac LKB1 were fed a control diet or a high-fat, high-sucrose diet for 4 months.
On the control diet, cardiac LKB1 hearts had normal structure and function. After 4 months of the high-fat, high-sucrose diet,
there was left ventricular hypertrophy and diastolic dysfunction in wild-type mice. In cardiac LKB1 (versus wild-type) mice, high-fat,
high-sucrose feeding caused more hypertrophy (619 versus 553 lm2, P<0.05), the de novo appearance of systolic dysfunction
(left ventricular ejection fraction; 41% versus 59%, P<0.01) with left ventricular dilation (3.6 versus 3.2 mm, P<0.05), and more
severe diastolic dysfunction with progression to a restrictive ﬁlling pattern (E/A ratio; 5.5 versus 1.3, P=0.05). Myocardial
dysfunction in hearts of cardiac LKB1 mice fed the high-fat, high-sucrose diet was associated with evidence of increased apoptosis
and apoptotic signaling via caspase 3 and p53/PUMA (p53 upregulated modulator of apoptosis) and more severe mitochondrial
dysfunction.
Conclusions-—Partial deﬁciency of cardiac LKB1 promotes the adverse effects of a high-fat, high-sucrose diet on the myocardium,
leading to worsening of diastolic function and the de novo appearance of systolic dysfunction. LKB1 plays a key role in protecting
the heart from the consequences of metabolic stress. ( J Am Heart Assoc. 2016;5:e002277 doi: 10.1161/JAHA.115.002277)
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T he increasing prevalence of obesity from dietary caloricexcess and physical inactivity exposes patients to the
risk of developing obesity-related metabolic heart disease
(MHD). The earliest manifestations of MHD are left ventricular
hypertrophy (LVH) and diastolic dysfunction, which is often
asymptomatic. With time, however, there may be progression
to clinical heart failure related to worsening diastolic
dysfunction and/or the appearance of systolic dysfunction.
The cellular mechanisms underlying the development and
progression of MHD are incompletely understood.
Liver kinase B 1 (LKB1; also known as serine/threonine
kinase 11 [STK11]) is a tumor-suppressor kinase that ismutated
in patients with Peutz-Jeghers syndrome and cancers1 that
affect cell growth andpolarity.2 LKB1 is also a potent activator of
the cellular energy sensor AMP-activated protein kinase
(AMPK).3 LKB1-mediated phosphorylation of the Thr172 site
on the AMPK-a catalytic subunit is a key regulatory step in the
cardioprotective activation of heart AMPK during myocardial
ischemia.4,5 AMPK exerts several potentially beneﬁcial actions
in themyocardium including insulin-independentGLUT4 translo-
cation,6 inhibition of hypertrophy,7 and possibly a decrease
in oxidative stress.8 LKB1 can also activate downstream
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signaling pathways in addition to AMPK,2,3 such as the sucrose
nonfermenting 1–related kinase (SNRK)9 and the sucrose
nonfermenting AMPK-related kinase (SNARK/NUAK2),10 for
which the functions in the heart are poorly understood.
We previously found that LKB1 is posttranslationally
modiﬁed by the reactive aldehyde 4-hydroxy-2-nonenal, or
HNE, in mice fed a high-fat, high-sucrose (HFHS) diet,11 and
in vitro studies show that HNE adduction of LKB1 at lysine 97
decreases its activity.12 This suggests that LKB1 activity may
be decreased in MHD, raising the possibility that impaired
LKB1 signaling contributes to the pathogenesis of MHD
through a decrease in cardioprotective signaling by AMPK
and/or other LKB1 targets.
Our aim was to investigate the role of LKB1 in mitigating
adverse effects on the heart from metabolic stress caused by
an HFHS diet, which we have shown leads to myocardial
hypertrophy, diastolic dysfunction, and impaired mitochon-
drial function.11,13 Mice with homozygous deﬁciency of
cardiac LKB1 develop severe systolic failure with 50%
mortality by the age of 4 months.14 To test the consequences
of a partial deﬁciency of cardiac LKB1, our ﬁrst goal was to
generate mice with cardiac-speciﬁc haplodeﬁciency for LKB1
(cardiac LKB1 f/+, Cre/+ [cLKB1+/]). Because the LKB1
axis plays an important role in noncardiac muscle, it was
important that LKB1 deﬁciency be cardiac speciﬁc. Our
second goal was to test the hypothesis that cLKB1+/ mice
would be more susceptible to the adverse effects of an HFHS
diet and, if so, to explore the mechanisms responsible.
Methods
Experimental Animals
Male mice heterozygous for cardiomyocyte-speciﬁc expres-
sion of the LKB1 gene were created by crossing LKB1 ﬂox/
ﬂox14 mice with mice expressing aMHCCre (alpha myosin
heavy chain-driven Cre recombinase) (Jackson Laboratory, Bar
Harbor, ME). Cardiomyocyte-speciﬁc LKB1+/ mice (LKB1 f/
+, Cre/+, which has one ﬂoxed copy of the LKB1 gene and
one copy of MHCCre, C-LKB1+/) were compared with wild-
type (WT) littermate controls (LKB1 f/+, no Cre). The
institutional animal care and use committee of Boston
University School of Medicine approved all animal experi-
ments and were in accordance with institutional guidelines.
HFHS Diet
Mice were fed an HFHS diet (35.5% fat [lard] and 26.3%
carbohydrates [sucrose]; Research Diets) or a control diet
(CD; 4.5% fat/76.3% corn starch) matched for micronutrients
for 12 weeks beginning at 12 to 20 weeks of age, as
previously described.11,15
Echocardiography
Two-dimensional and M-mode echocardiography was
performed on nonanesthetized mice (heart rate 650 beats
per minute) using an Acuson Sequoia C-256 machine with
a 15-MHz transducer, as described previously.11,16–18
Transmitral and tissue Doppler measurements of left
ventricular (LV) diastolic function was performed using a
VisualSonics Vevo 770 high-resolution machine and a
30-MHz transducer.11,16–18 All measurements of diastolic
function were performed on mice anesthetized with isoﬂu-
rane, titrated to a heart rate of 400 to 500 beats per
minute.
Immunoblotting
Whole-heart protein lysates made from freeze-clamped hearts
using lysis buffer (HEPES pH 7.4 [20 mmol/L], b-glycerol
phosphate [50 mmol/L], EGTA [2 mmol/L], DTT [1 mmol/L],
NaF [10 mmol/L], NaVO4 [1 mmol/L], Triton X-100 [1%],
glycerol [10%,] and 1 protease inhibitor complete mini tablet-
EDTA free/20 mL [Roche]) were subjected to SDS-PAGE with
protein content quantiﬁed using the Bradford method (Bio-
Rad). Following transfer, nitrocellulose membranes were
probed with primary antibodies (LKB1 [D60C5; Cell Signal-
ing]), LKB1 (M-18; Santa Cruz Biotechnology), phospho-LKB1
(Ser428/431; Cell Signaling), phospho-AMPK (Thr172; Cell
Signaling), total AMPK a2 (Santa Cruz Biotechnology), GAPDH
(Abcam), STRAD (S-17; Santa Cruz Biotechnology), MO25
(Cell Signaling), VDAC (Abcam), PUMA (Cell Signaling), SNRK
(Sigma-Aldrich), cleaved and total caspase 3 (Cell Signaling),
and visualized using LI-COR secondary antibodies and the LI-
COR Odyssey IR imager. Densitometry was quantiﬁed using
Odyssey software. Primary antibody directed against p53 (Cell
Signaling) was detected using enhanced chemiluminescence
and quantiﬁed using MultiGauge software (Fujiﬁlm).
LKB1 Immunoprecipitation and Activity Assay
LKB1 was immunoprecipitated from whole-heart lysates using
LKB1 M-18 antibody conjugated to protein G beads (GE
Healthcare). Samples were either subjected to immunoblot-
ting or used for kinase activity assays by washing twice with
homogenization buffer (Tris [125 mmol/L], EDTA [10 mmol/
L], EGTA [10 mmol/L]), twice with kinase wash buffer (HEPES
[40 mmol/L], NaCl [80 mmol/L], EDTA [0.8 mmol/L], MgCl2
[5 mmol/L], DTT [0.8 mmol/L], glycerol [8%], pH 7.0), and
then incubated with kinase assay buffer (HEPES [80 mmol/
L], NaCl [160 mmol/L], EDTA [1.6 mmol/L], DTT [0.8 mmol/
L], glycerol [16%], pH 7.5) containing the LKBtide synthetic
substrate (300 lmol/L; Millipore), ATP (200 lmol/L), and
[c-32P]ATP (5 lCi). After incubation at 30°C for 20 minutes,
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the reaction mixture was spotted on P81 paper, washed
repeatedly with cold phosphoric acid, and dried in acetone,
and radioactivity was measured by liquid scintillation
counting.
Mitochondrial Function Assays
Isolated mitochondrial oxygen consumption rates were mea-
sured using a Seahorse XF24 oxygen ﬂux analyzer, as
described previously,17 and ice-cold mitochondrial assay
solution (70 mmol/L sucrose, 220 mmol/L mannitol,
5 mmol/L KH2PO4, 5 mmol/L MgCl2, 2 mmol/L HEPES,
1 mmol/L EGTA, 0.2% BSA fatty acid-free, pH 7.4) plus 109
substrates (complex I: 50 mmol/L pyruvate and 50 mmol/L
malate; complex II: 50 mmol/L succinate and 20 lmol/L
rotenone in mitochondrial assay solution). The 4 sequential
injection ports of the Seahorse cartridge contained the
following materials: Port A had 50 lL of 109 substrate and
2.5 mmol/L ADP, port B had 55 lL of 20 lmol/L oligomycin,
port C had 60 lL of 40 mmol/L FCCP, and port D had 65 lL
of 40 lmol/L antimycin A. State III was determined after port
A injection, and state IV was determined after port B injection
and uncoupled after port C. Isolated heart mitochondria ATP
synthesis rates for complex I and II substrates were deter-
mined using modiﬁcations of the luciferin/luciferase-based
ATP Bioluminescence Assay Kit CLS II (Roche), as described
previously.17
Quantitative reverse transcription polymerase
chain reaction
Total RNA was extracted from frozen hearts using the mirVana
miRNA Isolation Kit (Applied Biosystems), Life Technology 2X
Master Mix was used for reverse transcription polymerase
chain reaction to DNA, and quantitative polymerase chain
reaction was performed with TaqMan PCR Master Mix and
TaqMan primers (Applied Biosystems) speciﬁc for mouse
SNRK (Mm00505254_m1), STK11 (LKB1) and Stk11 (LKB1;
Mm00488470_m1), PRKAA2 (AMPK a2; Mm01264789_m1),
and NUAK2 (Snark; Mm00546961_m1), as described
previously.17
TUNEL Staining
Apoptosis was assessed using an In Situ Cell Death Detection
Fluorescein Kit (Roche Applied Science), according to the
manufacturer’s instructions, as described previously, using
ﬂuorescein-labeled deoxyuridine triphosphate to identify apop-
totic nuclei using ﬂuorescence microscopy.18 Random sections




Figure 1. Characterization of the cLKB1+/ mouse. A, Total cardiac LKB1 expression (n=4 to 6, 56%;
*P<0.0001) and activity (40%, *P=0.01) are decreased in cLKB1+/ hearts. B, Expression of the LKB1
adapter proteins STRAD and MO25 is unchanged in cLKB1+/ hearts. C, Pull-down of endogenous LKB1
protein is speciﬁc in the heart, using hearts without cardiac LKB1 (LKB1 F/F, Cre/+, or LKB1/) as a
negative control. Faint band in LKB1/ hearts represents noncardiomyocyte or atrial LKB1 protein (see
Figure S1). cLKB1+/ indicates cardiac-speciﬁc haplodeﬁciency for liver kinase B1; LKB1, liver kinase B1.
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animal. The number of apoptotic nuclei was expressed per
10 000 cardiomyocytes, using colocalization of dUTP, anti–a-
sarcomeric actin (Sigma-Aldrich), and Hoechst 33258 to
identify apoptotic nuclei, cardiomyocytes, and nuclei,
respectively.
Microscopy for Myocyte Cross-Sectional Area
and Immunohistochemistry
Cardiomyocyte cross-sectional area and ﬁbrosis were mea-
sured, as described previously.18 Brieﬂy, sections were
stained with hematoxylin and eosin and examined under a
light microscope (BX40; Olympus). Five random ﬁelds from
each of 4 sections per animal were analyzed, and 60
cardiomyocytes per animal were measured. The quantiﬁcation
of cardiomyocyte cross-sectional area was determined with
ImageJ software (National Institutes of Health). To assess
ﬁbrosis, sections were stained with a Masson trichrome kit
(Sigma-Aldrich) and examined under a light microscope
(BX40; Olympus).
Statistical Analysis
Data are presented as meanSEM for continuous variables.
Differences between 2 means were tested using an unpaired,
nonparametric t test (Mann–Whitney), whereas 1-way ANOVA
with Bonferroni post test was used for multiple comparisons
using Prism 5 (version 5.0f; GraphPad Software Inc). For all
analyses, a P value of <0.05 was considered to be statistically
signiﬁcant.
Results
Phenotypic Characterization of cLKB1+/ Hearts
We generated mice with a single copy of the LKB1 gene
expressed in cardiomyocytes (cLKB1+/). Total cardiac LKB1
expression is decreased by 56% (P<0.0001) in cLKB1+/
hearts, whereas the expression of the LKB1 adapter proteins
STRAD and MO25 is normal (Figure 1). Decreased expression
of LKB1 in the cLKB1+/ hearts is associated with a 40%
A B c
D E F
Figure 2. Detrimental effect of HFHS diet on cLKB1+/ heart function. A, An HFHS diet increases total wall thickness in WT hearts and in
cLKB1+/ hearts. #P=0.14 vs WT fed HFHS. B, Relative wall thickness (LV septum plus LV posterior wall divided by LVIDd) is unchanged in
cLKB1+/ hearts with and without HFHS feeding, demonstrating no evidence of eccentric LV remodeling. C, LV diastolic internal dimension is
signiﬁcantly increased in hearts from HFHS-fed cLKB1+/ mice. #P=0.04 vs WT fed HFHS. D, LV ejection fraction is signiﬁcantly reduced in
hearts from cLKB1+/ mice on an HFHS diet. #P=0.005 vs WT fed HFHS. E, Mitral annular tissue Doppler velocity (em) is reduced in hearts from
WT fed HFHS and to a greater extent in hearts from cLKB1+/ mice fed HFHS. #P=0.008 vs WT fed HFHS. F, There is a marked increase in the
transmitral Doppler inﬂow velocity in hearts from cLKB+/ mice fed HFHS. #P=0.06 vs WT fed HFHS). This is consistent with marked diastolic
dysfunction and restrictive LV ﬁlling. Hearts from WT fed HFHS demonstrated a mild reduction in E/A ratio consistent with impaired relaxation.
n=5 to 7 per group. cLKB1+/ indicates cardiac-speciﬁc haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-sucrose; LKB1, liver kinase B1;
LV, left ventricular; LVIDd, LV diastolic internal dimension; WT, wild type.
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decrease in LKB1 activity, as assessed using an LKB1
immunoprecipitation kinase activity assay (P=0.01) (Figure 1).
The speciﬁcity for LKB1 pull-down was conﬁrmed using
lysates from cLKB1/ hearts as a negative control
(Figure 1). Interestingly, there was persistence of an LKB1
phospho-Ser428/431 signal in hearts with homozygous
deletion of LKB1 (LKB1/) (Data S1 and Figure S1),
suggesting that this commonly used measure of LKB1 activity
is not speciﬁc in the heart.
In contrast to the severe phenotype of LKB1/ hearts,
there were no changes in LV wall thickness, chamber size, or
systolic or diastolic function in cLKB1+/ hearts (versus WT)
at ages up to 6 months (Figure S2). Consequently, partial
cardiac-speciﬁc LKB1 deﬁciency per se does not lead to
adverse cardiac remodeling or dysfunction under nonstress
conditions.
HFHS Diet Causes Severe Adverse Remodeling in
cLKB1+/ Hearts
We previously showed that WT mice fed an HFHS diet
developed cardiac hypertrophy and diastolic dysfunction with
preserved systolic function.11 To evaluate the role of the LKB1
axis in mediating the heart’s response to metabolic stress,
cLKB1+/ mice (n=24) were fed an HFHS diet for 4 months
and compared with WT littermates (n=23). As expected, WT
mice fed an HFHS diet developed LV hypertrophy and diastolic
dysfunction with decreases in Em and E/A (Figure 2). Hearts
from HFHS-fed cLKB1+/ mice developed more hypertrophy
than CD-fed cLKB1+/ mice, as assessed by echocardiog-
raphy (Figure 2) and by histology with measurement of
cardiomyocyte cross-sectional area (Figure 3). HFHS feeding
led to an increase in oxidative stress in cLKB1+/ hearts that
was similar to WT (Figure S3) and induction of antioxidant
gene expression (data not shown). In WT mice, HFHS feeding
had no effect on LV dimensions or ejection fraction. In
contrast, in cLKB1+/ mice, HFHS feeding caused LV dilation
(LV diastolic internal dimension; P=0.03 versus WT fed HFHS)
and systolic dysfunction (LV ejection fraction; P=0.001 versus
WT fed HFHS) (Figure 2). Diastolic function was also more
severely impaired in hearts from cLKB1+/ versus WT mice
on an HFHS diet, with a larger decrease in Em by tissue
Doppler (0.012 versus WT fed HFHS). Likewise, HFHS feeding
caused a slowed ﬁlling pattern with a decrease in E/A
by transmitral Doppler in WT mice, whereas in cLKB1+/
mice, HFHS feeding caused a marked restrictive pattern with
Figure 3. Increased cardiomyocyte cross-sectional area in cLKB1+/ hearts after HFHS diet. Dietary
challenge with HFHS feeding more severely increased (left panel) cardiomyocyte area in cLKB1+/ hearts
compared with hearts from WT fed HFHS and controls. #P<0.05 vs WT fed HFHS. Cardiac ﬁbrosis was
increased in both WT and cLKB1+/ hearts following HFHS feeding (right panel). CD indicates control diet;
cLKB1+/, cardiac-speciﬁc haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-sucrose; LKB1, liver
kinase B1; WT, wild type.
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a 5-fold increase in E/A (P=0.012 versus WT CD). The
increased myocyte hypertrophy and diastolic dysfunction
occurred in concert with increased myocardial ﬁbrosis in both
WT and cLKB1+/ hearts (Figure 3).
Of note, 17% (4 of 24) of cLKB1+/ mice on an HFHS diet
died compared with none of the WT mice on an HFHS diet (0
of 23). No WT or cLKB1+/ mice on the CD died. In contrast
to WT mice on the HFHS diet, cLKB1+/ mice developed LV
systolic dysfunction with chamber dilation, more severe
diastolic dysfunction with progression to restrictive ﬁlling,
and increased mortality with premorbid hunched posture and
poor grooming, which can be a sign of congestive heart
failure.
Effect of an HFHS Diet on LKB1 Activity and
AMPK Activation
In WT mice, cardiac LKB1 activity was reduced 28% after
4 months on the HFHS diet, but the decrease did not reach
statistical signiﬁcance (P=0.19) (Figure 4). Of note, we found
that in WT mice, HFHS feeding for 8 months decreased LKB1
activity by 32% (P=0.02) with no change in LKB1 expression
(Figure S4). In cLKB1+/ hearts, 4 months of an HFHS diet
did not further reduce LKB1 activity.
Downstream AMPK Thr172 phosphorylation was reduced
by 48% in cLKB1+/ hearts (P=0.001 versus WT) on CD
and by 35% (P=0.07) in WT hearts on the HFHS (versus CD)
diet (Figure 4). On the HFHS diet, AMPK Thr172 phospho-
rylation in cLKB1+/ hearts was decreased by 31%, which
tended to be lower than in hearts of HFHS-fed WT mice
(P=0.15).
Increased Expression of SNRK, a Downstream
LKB1 Target, in Hearts From HFHS-Fed Mice
Although AMPK is the best recognized LKB1 downstream
target, other targets undergo direct activation by LKB1, such
as the >12 members of the AMPK-related kinase (ARK)
family.2,19 A member of the ARK family, SNRK, may be
important for limiting cellular proliferation in colon cancer9
and inhibiting neuronal apoptosis.20 Of note, it was shown
recently that cardiomyocyte-speciﬁc loss of SNRK causes
mitochondrial dysfunction, LV dilation, and reduced systolic
function.21 The similarity of this phenotype to the one we
observed in HFHS-fed cLKB1+/ mice raised the possibility
that SNRK is an important target for LKB1 in MHD.
We attempted, without success, to measure endogenous
SNRK activity via an immunoprecipitation kinase activity
approach (analogous to LKB1 activity) using 6 different anti-
SNRK antibodies. Furthermore, there is no known posttrans-
lational marker, analogous to AMPK phosho-Thr172, for
measuring SNRK activity; however, we found that HFHS
feeding increased SNRK expression, as reﬂected by a 40%
(P=0.01) increase in SNRK mRNA and a 100% increase in
SNRK protein (P=0.03) in WT hearts. Likewise, in hearts from
HFHS-fed cLKB1+/ mice, there were 52% (P=0.002) and
64% (P=0.03) increases in SNRK mRNA and protein, respec-
tively (Figure 5). There were no changes in the expression of
Figure 4. LKB1 activity and AMPK phosphorylation are reduced
after an HFHS diet. Cardiac LKB1 activity was reduced in cLKB1+/
 mice vs WT on CD (*P=0.003) and nonsigniﬁcantly reduced at
4 months of an HFHS diet in WT mice (P=0.19) (top panel). The
HFHS diet did not further reduce LKB1 activity in cLKB1+/
hearts. AMPK Thr172 phosphorylation was reduced in cLKB1+/
hearts (#P=0.001 vs WT) (bottom panel) on a CD and in WT hearts
on an HFHS diet ( P=0.07 vs CD). On an HFHS diet, AMPK Thr172
phosphorylation in cLKB1+/ was decreased by 31%, which
tended to be lower than in HFHS-fed WT hearts ($P=0.15). n=5 to 7
per group. CD indicates control diet; cLKB1+/, cardiac-speciﬁc
haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-sucrose;
LKB1, liver kinase B1; p-AMPK, phospho-Thr172 AMPK; t-AMPK,
total AMPK; WT, wild type.
DOI: 10.1161/JAHA.115.002277 Journal of the American Heart Association 6
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either AMPK a2 or SNARK/NUAK2 (another ARK) with the
HFHS diet, showing that induction of SNRK was not ubiqui-
tous among members of the ARK family.
Increased Apoptosis in Hearts From HFHS-Fed
cLKB1+/ Mice
The HFHS diet increased the percentage of TUNEL-positive
cardiomyocyte nuclei in both WT (P=0.04 versus WT CD) and
cLKB1+/ hearts (P=0.02 versus cLKB1+/ CD) (Figure 6).
The HFHS diet–induced increase in TUNEL-positive nuclei
tended to be higher in cLKB1+/ versus WT hearts (P=0.19).
This trend was associated with increases in cleaved caspase 3
and the expression of proapoptotic p53 and PUMA (Figure 6).
There were no changes in the expression of the antiapoptotic
proteins BCL2, BCLxl, and MCL1 (data not shown).
Mitochondrial Dysfunction in Hearts From HFHS-
Fed cLKB1+/ Mice
Mitochondrial respiration andmaximal ATP productionwere not
different in mitochondria isolated from cLKB1+/ versus WT
hearts of CD-fed mice (data not shown); however, after
4 months of HFHS feeding, maximal ATP production with both
complex I and II substrates was decreased inmitochondria from
cLKB1+/ (versusWT) hearts (Figure 7). Likewise, complex II–
driven state III, state IV, and uncoupled respiration were
decreased in mitochondria from cLKB1+/ (versus WT) hearts
Figure 5. SNRK expression is upregulated by HFHS diet. SNRK protein level (upper left panel) is upregulated by HFHS diet in both WT and
cLKB1+/ (*P=0.04 vs CD) and is measured at the transcript level by quantitative reverse transcription polymerase chain reaction (upper right)
(*P=0.0004 vs WT fed HFHS). LKB1 expression is reduced 50% in cLKB1 hearts and is not induced by an HFHS diet (lower left panel)
(#P=0.005 vs WT fed HFHS). AMPK a2 and SNARK/NUAK2 transcript expression is not changed in cLKB1+/ hearts with a control or HFHS
diet. n=5 to 8 per group. CD indicates control diet; cLKB1+/, cardiac-speciﬁc haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-sucrose;
LKB1, liver kinase B1; SNARK, sucrose nonfermenting AMPK-related kinase; SNRK, sucrose nonfermenting 1–related kinase; WT, wild type.
DOI: 10.1161/JAHA.115.002277 Journal of the American Heart Association 7
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(Figure 7). Mitochondrial mass, as reﬂected by VDAC expres-
sion and complex II succinate dehydrogenase subunit A
expression, was not different in cLKB1+/ versus WT hearts
(data not shown). Respiration using complex I substrates was
unchanged.
Discussion
Obesity-related MHD is increasing at an alarming rate.22
Hallmarks of obesity-related MHD include LVH and diastolic
dysfunction, and with time, there is often progression to
clinical heart failure due to more severe diastolic dysfunction
and/or the development of systolic dysfunction.23 Our goal
was to investigate the role of the key energetic signaling
enzyme LKB1 in mitigating the response of the heart to the
metabolic challenge of an HFHS diet. As we expected, the
adverse effects of HFHS feeding were worse in cLKB1+/
mice, which exhibited greater LVH, more severe diastolic
dysfunction, and the development of de novo systolic
dysfunction that was associated with increased mortality.
Because we previously observed that HFHS feeding per se
decreases LKB1 activity by means of HNE adducts,12 we
expected that cLKB1+/ mice with a 50% decrease in LKB1
protein would exhibit a further decrease in LKB1 activity when
exposed to HFHS feeding. Contrary to this thesis, we found
that LKB1 activity in cLKB1+/ mice was not lowered further
by HFHS feeding. These ﬁndings suggest that a 50% decrease
in LKB1 activity per se is not detrimental to cardiac function
but rather makes the heart more susceptible to the adverse
effects of metabolic stress.
Speciﬁcally, this study provides several new ﬁndings. First,
in contrast to mice with complete absence of cardiac LKB1,
the 50% decrease in LKB1 in cLKB1+/ mice had no effect
on cardiac structure or function. Second, HFHS feeding, which
led to LVH and moderate diastolic dysfunction, decreased
LKB1 and AMPK signaling and increased the expression of
SNRK, a member of the ARK family that is activated by
LKB1.24 Third, in cLKB1+/ (versus WT) mice, HFHS feeding
caused more severe diastolic dysfunction, cardiomyocyte
hypertrophy, the de novo appearance of systolic dysfunction,
early death, increased apoptotic signaling, more ﬁbrosis, and
worse mitochondrial function. Together, these ﬁndings sug-
gest that LKB1 plays a key role in mitigating the cardiac
response to a dietary metabolic challenge.
Figure 6. Increased apoptosis in cLKB1+/ hearts. HFHS feeding increased the percentage of TUNEL-
positive cardiomyocyte nuclei (top left panel) in both WT and cLKB1+/ hearts (*P=0.02 vs cLKB1+/ fed
CD). This coincided with an increase in cleaved/total caspase 3 (*P=0.03 vs WT fed HFHS) (bottom left
panel), increased p53 expression (*P=0.0004 vs WT fed HFHS) (top right panel), and PUMA expression
(*P=0.02 vs WT fed HFHS) (bottom left panel). n=5 to 7 per group. CD indicates control diet; cLKB1+/,
cardiac-speciﬁc haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-sucrose; WT, wild type.
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Phenotype of the cLKB1+/ Mouse
In prior studies, homozygous (100%) deletion of cardiomy-
ocyte LKB1 (LKB1/) led to a severely dysfunctional
cardiac phenotype with atrial and LV dilation, profound
systolic failure, and arrhythmias beginning at 4 weeks of
age and progressing to death before 6 months.14,25 The
cLKB1+/ mouse is novel and provides novel insight
regarding the role of LKB1 in the response to pathophysio-
logical stimuli. It is noteworthy that partial deﬁciency of
cardiac LKB1 expression and activity in the cLKB1+/ mouse
had no effect on cardiac structure or function in the absence
of dietary stress (Figure S2). The lack of a cardiac phenotype
in the cLKB1+/ mouse indicates that LKB1 activity on the
order of 50% is sufﬁcient to support normal cardiac structure
and function.
Effects of HFHS Feeding on the LKB1–AMPK Axis
We previously showed that HFHS feeding for 4 to 8 months
causes LVH, diastolic dysfunction, increased oxidative stress,
and mitochondrial impairment.11,15 In the present study,
HFHS feeding for 4 months likewise caused LVH and diastolic
dysfunction that coincided with increased oxidative stress
deﬁned by accumulation of cardiac HNE, a reactive aldehyde
generated by lipid peroxidation. HNE has been shown to
inhibit LKB1 activity,7 at least in part, via adduction to lysine
97.12 In the present study, we found that HFHS feeding for 4
and 8 months decreased LKB1 activity by 28% and 32%,
respectively, although only the decrease at 8 months reached
signiﬁcance; however, the modest decrease in LKB1 activity
with 4 months of HFHS feeding was associated with a
signiﬁcant 35% decrease in AMPK activity.
Figure 7. Mitochondrial dysfunction in cardiac mitochondria isolated from HFHS-fed hearts. Using
mitochondrial complex I substrates, there was no difference in mitochondrial respiration measured in
isolated heart mitochondria (top left), but there was a signiﬁcant reduction in the maximal rate of ATP
synthesis (*P=0.04 vs WT fed HFHS). Using complex II substrates, the rates of maximal ADP-stimulated
respiration (state III), proton leak (state IV), and FCCP-uncoupled respiration were all signiﬁcantly decreased
in cLKB1+/ hearts from HFHS-fed mice (*P<0.05 vs WT fed HFHS) (bottom left). In addition, the maximal
rate of ATP synthesis was reduced in HFHS-fed cLKB1+/ hearts (*P=0.02 vs WT fed HFHS). n=7 per
group. cLKB1+/ indicates cardiac-speciﬁc haplodeﬁciency for liver kinase B1; HFHS, high-fat, high-
sucrose; WT, wild type.
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HFHS Feeding in cLKB1+/ Mice
Although cLKB1+/ mice have no cardiac phenotype at
baseline, they have a markedly worse response to HFHS
feeding, with more severe diastolic dysfunction and the de
novo appearance of systolic dysfunction and early death. This
ﬁnding suggests that the LKB1–AMPK axis may play an
important role in opposing the adverse effects of HFHS
feeding. In WT mice, the 28% decrease in LKB1 activity
caused by HFHS feeding was less than the 50% decrease in
the cLKB1+/ mouse; therefore, these observations suggest
that LKB1, despite a modest decrease in activity, exerts a
protective effect in the setting of metabolic stress.
We previously showed that HFHS feeding leads to mito-
chondrial dysfunction with increased reactive oxygen species
production, decreased ATP synthesis, and oxidative post-
translational modiﬁcations of mitochondrial proteins that may
contribute to dysfunction.15 In this regard, it is noteworthy
that in cLKB1+/ mice, HFHS feeding caused more severe
mitochondrial dysfunction, reﬂected by larger decreases in
maximal ATP production with both complex I and II sub-
strates. LKB1 deﬁciency may thus contribute to worsening
myocardial dysfunction by causing energetic limitation of key
energy-dependent processes such as sarcoplasmic reticulum
calcium reuptake. Acting through AMPK, LKB1 may oppose
the effects of HFHS feeding on mitochondrial function by
supporting mitochondrial biogenesis26 or decreasing oxidative
stress.27 In cLKB1+/ mice, HFHS feeding was also asso-
ciated with evidence of increased apoptotic signaling and
activity that may have contributed to the appearance of
systolic heart failure, reﬂected by dilation and a fall in ejection
fraction. Apoptotic myocytes were increased with HFHS
feeding and tended to be more increased in cLKB1+/ mice
and were associated with signiﬁcant increases in caspase 3
activation and increased expression of p53 and PUMA. LKB1
interacts with p53 in the nucleus,28 and an inverse relation-
ship between LKB1/AMPK activity and p53 abundance has
been observed.29 Consequently, diminished LKB1 activity in
the hearts of HFHS-fed cLKB1+/ mice may be a potential
factor in promoting a deleterious proapoptotic signaling
cascade.
Role of Decreased AMPK Activity and Other LKB1
Targets
HFHS feeding caused a greater decrease in AMPK activity in
cLKB1+/ mice than in WT mice, although the difference was
small and did not reach signiﬁcance. It is possible that this
modest decrease in AMPK in the cLKB1+/ mice contributes
to more deleterious effects of an HFHS diet in these mice.
Other downstream LKB1 targets are now recognized such as
SNRK and SNARK/NUAK2.2,19,30 Although the functions of
these LKB1 targets are not fully understood, it is noteworthy
that mice with cardiomyocyte-speciﬁc deletion of SNRK
develop cardiac and mitochondrial dysfunction similar to that
observed in HFHS-fed cLKB1+/ mice.21 It is of interest that
expression of SNRK is increased by HFHS feeding, suggesting
that expression may be a compensatory response to dietary
stress. Although it is not currently possible to measure SNRK
activity, it seems likely that LKB1–SNRK signaling would be
impaired in the cLKB1+/ mice, possibly removing a
potentially important compensatory mechanism.
In summary, partial LKB1 deﬁciency promotes a deleteri-
ous response to HFHS feeding with more severe diastolic
dysfunction, the de novo appearance of systolic dysfunction,
mitochondrial dysfunction, and increased apoptotic signaling.
An alternative view of these results is that HFHS feeding of
cLKB1+/ mice unmasks a phenotype not dissimilar to that
observed with severe (homozygous) LKB1 deﬁciency. In either
case, our ﬁndings indicate that LKB1 signaling plays an
important role in protecting the heart from the structural and
functional effects of dietary stress. Our observation that
SNRK, a newly recognized target of LKB1, is upregulated by
HFHS feeding raises the possibility that the adverse effects of
LKB1 deﬁciency involve a decrease in SNRK signaling. Future
studies that elucidate the mechanisms by which LKB1
protects the heart from pathological stimuli such as dietary
excess may lead to novel approaches to metabolic and other
stresses.
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Isolated Mouse Heart Perfusions 
 Mice were heparinized (100 U IP) and anesthetized by sodium pentobarbital (150 
mg/kg IP). The heart was excised and retrograde perfused in the Langendorff mode at a 
constant pressure of 80 mm Hg at 37°C with an oxygenated (95% O2 and 5% CO2 (pH 
7.4) perfusate (NaCl 118 NaHCO3 25, KCl 5.3, CaCl2 1.8, MgSO4 1.2, glucose 10, and 
pyruvate 0.5).  Hearts were paced at a constant rate of 7.5 Hz (450 bpm) for 10 
minutes, then subjected to global, no-flow ischemia (non-paced) for 10 minutes, and 
freeze-clamped with Wollenberger tongs that were precooled in liquid nitrogen 
 
Immunohistochemistry for 4-Hydroxy-trans-2-nonenal (HNE): 
Left ventricular tissue sections (4 μm) were blocked with 10% goat serum in phosphate-
buffered saline, incubated with mouse anti-HNE monoclonal antibody, and incubated 
Miller et al. Supplement, page 2 
with goat biotin-conjugated anti-mouse IgG (Vector Laboratory, Burlingame, CA). The 
sections were incubated with avidin and biotinylated horseradish peroxidase 
macromolecular complex (Vector Laboratory) and stained with 3-amino-9-
ethylcarbazole (Vector Laboratory) and hematoxylin (Vector Laboratory). The samples 
were examined under a light microscope (BX 40, Olympus). 
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Online Supplemental Figure Legends 
 
Figure S1.  Lack of specificity of LKB1 phoshpo-Ser428/431 antibody and 
specificity of total LKB1 antibody.  An obvious pSer431 LKB1 band is present in 
hearts from all genotypes of LKB1 mice, including LKB1-/- hearts (left panel), while 
LKB1 protein is virtually undetectable in LKB1 ventricles (A=atria, V=venrticles) 
Figure S2.   Echocardiographic characterization of cLKB1+/- hearts up to 6 months of 
age.  
Figure S3.  Hydroxynonenol staining (HNE) by immunohistochemistry  
 
Figure S4.. Reduced LKB1 isolated kinase activity in WT mice fed HFHS diet for 8 
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